A5009044758- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Cancer therapeutics and mechanisms
- Advanced Breast Cancer Therapies
- Retinoids in leukemia and cellular processes
- Hematopoietic Stem Cell Transplantation
- Medical Imaging Techniques and Applications
- Glycosylation and Glycoproteins Research
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- CNS Lymphoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Health and Medical Research Impacts
- Immune Cell Function and Interaction
Lymphoma Research Foundation
2020-2023
Georgetown University
2012-2022
MedStar Georgetown University Hospital
2018-2020
Georgetown University Medical Center
2008-2019
Immungenetics (Germany)
2019
University Hospital Ulm
2019
Georgetown Lombardi Comprehensive Cancer Center
2016
Cancer Research Center
1997-2013
Fred Hutch Cancer Center
1997-2013
University of Rochester Medical Center
2013
To develop guidelines for performing and interpreting positron emission tomography (PET) imaging treatment assessment in patients with lymphoma both clinical practice trials.An International Harmonization Project (IHP) was convened to discuss standardization of trial parameters lymphoma. An subcommittee developed consensus recommendations based on published PET literature the collective expertise its members use Only subsequently endorsed by all IHP subcommittees were adopted.PET after...
Fludarabine is an effective treatment for chronic lymphocytic leukemia that does not respond to initial with chlorambucil. We compared the efficacy of fludarabine chlorambucil in primary leukemia.
Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein kinase-1ε, exhibits improved selectivity for PI3Kδ compared other inhibitors. This phase IIb trial was designed to evaluate the efficacy safety umbralisib patients R/R iNHL.In this multicohort, open-label, study,...
The nucleoside analogs fludarabine, 2'-deoxycoformycin (DCF), and 2-chlorodeoxyadenosine (CdA), commonly used in the treatment of patients with indolent lymphoid malignancies such as chronic lymphocytic leukemia (CLL) hairy cell (HCL), are associated myelosuppression profound prolonged immunosuppression. These complications raise possibility an increase secondary whose disease already places them at greater risk. purpose present study was to assess frequency second tumors CLL who treated...
Background A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) from the National Cancer Institute showed promising activity in untreated diffuse large B-cell lymphoma. The Leukemia Group B conducted a study to determine if these results could be reproduced multi-institutional setting.Design Methods included 69 patients with lymphoma at least 18 years age stage II. Radiaton therapy was not permitted on study. Median 58...
PURPOSE: Curative up-front regimens for non-Hodgkin’s lymphomas contain doxorubicin, vincristine, and cyclophosphamide, whereas salvage generally non–cross-resistant agents. We hypothesized that agents may be highly effective developed an infusional regimen based on in vitro evidence of increased efficacy. PATIENTS AND METHODS: A prospective phase II study etoposide, doxorubicin over 96 hours with bolus cyclophosphamide oral prednisone (EPOCH) was performed 131 patients relapsed or resistant...
Suramin sodium is a reverse transcriptase inhibitor with in vitro activity against the human immunodeficiency virus (HIV), causative agent of acquired syndrome (AIDS). Ninety-eight patients AIDS manifest as opportunistic infections (n = 38), Kaposi's sarcoma AIDS-related complex 20), or AIDS-associated non-Hodgkin's lymphoma (NHL) 2) were treated suramin at 0.5,1.0, 1.5 g/wk for six weeks followed by maintenance therapy 0.5 1.0 g/wk. Of 72 who HIV culture positive before and assessable...
Background In the present study, prognostic impact of minimal residual disease during treatment on time to progression and overall survival was analyzed prospectively in patients with mantle cell lymphoma treated Cancer Leukemia Group B 59909 clinical trial.Design Methods Peripheral blood bone marrow samples were collected different phases study for analysis. Minimal status determined by quantitative polymerase chain reaction IgH and/or BCL-1/JH gene rearrangement. Correlation determined....